We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.
TODAY'S HIGH
680
TODAY'S LOW
656.45
52 WEEK HIGH
774
52 WEEK LOW
600.3
% of Shares Held by
All Insider
78.45%
% of Shares Held by
Institutions
14.16%
% of Float Held by
Institutions
65.74%
Number of Institutions
Holding Shares
33
MARKET CAP
9194.35 Cr.
ETERPRISE VALUE
9232.82 Cr.
NO. OF SHARES
13.59 Cr.
BOOK VALUE
148.94
DIV. YIELD
7.35%
DEBT
269.09 Cr.
GROSS PROFIT
1062.13 Cr.
CASH
70.95 Cr.
REVENUE
1476.55 Cr.
REVENUE/SHARE
108.599
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | 0 | -294.63 Cr. | 287.99 Cr. | 34.96 Cr. |
| Change To Liabilities | 0 | 2.56 Cr. | 15.93 Cr. | -6.65 Cr. |
| Total cashflows from Investing Activities | 0 | -323.35 Cr. | 123.23 Cr. | -5.05 Cr. |
| Net Borrowings | 0 | -5.93 Cr. | -184.11 Cr. | -200.21 Cr. |
| Total Cash from Financing Activities | 0 | -82.39 Cr. | -334.59 Cr. | -221.05 Cr. |
| Other Liabilities | 0 | 11.85 Cr. | -6.97 Cr. | -11.82 Cr. |
| Total Assets | 0 | 0 | 0 | 89.20 Lakhs |
| Net Income | 0 | 355.13 Cr. | 296.49 Cr. | 290.79 Cr. |
| Change in Cash | 0 | -30.39 Cr. | 59.80 Cr. | -3.10 Cr. |
| Effect of Exchange Rate | 0 | 0 | 0 | 0 |
| Total Cash from Operating Activities | 0 | 375.36 Cr. | 271.16 Cr. | 222.99 Cr. |
| Depreciation | 0 | 42.30 Cr. | 49.85 Cr. | 36.05 Cr. |
| Other Cashflows from Investing Activities | 0 | -4 Lakhs | 1.29 Cr. | 8.56 Cr. |
| Dividends Paid | 0 | -74.67 Cr. | -38.96 Cr. | -38.96 Cr. |
| Change to Inventory | 0 | -24.99 Cr. | 13.17 Cr. | -17.20 Cr. |
| Change to Account Receivables | 0 | 15.89 Cr. | -74.78 Cr. | -17.55 Cr. |
| Other Cashflows from Financing Activities | 0 | -1.78 Cr. | -11.51 Cr. | -21.73 Cr. |
| Change to Net Income | 0 | -28.08 Cr. | -22.93 Cr. | -50.91 Cr. |
| Capital Expenditures | 0 | -25.76 Cr. | -151.28 Cr. | -38 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 0 | 394.49 Cr. | 331.35 Cr. | 317.35 Cr. |
| Minority Interest | 0 | 20 k | 20 k | 18.31 Cr. |
| Net Income | 420.25 Cr. | 387.60 Cr. | 321.85 Cr. | 308.88 Cr. |
| Selling General Administrative | 0 | 243.91 Cr. | 231.68 Cr. | 245.29 Cr. |
| Gross Profit | 1067.65 Cr. | 950.71 Cr. | 882.91 Cr. | 809.58 Cr. |
| Ebit | 420.25 Cr. | 387.60 Cr. | 321.85 Cr. | 308.88 Cr. |
| Operating Income | 420.25 Cr. | 387.60 Cr. | 321.85 Cr. | 308.88 Cr. |
| Other Operating Expenses | 330.44 Cr. | 276.20 Cr. | 279.12 Cr. | 219.05 Cr. |
| Interest Expense | 0 | -1.80 Cr. | -2.16 Cr. | -22.89 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 0 | 39.36 Cr. | 34.84 Cr. | 26.21 Cr. |
| Total Revenue | 1326.16 Cr. | 1192.64 Cr. | 1058.18 Cr. | 967.20 Cr. |
| Total Operating Expenses | 905.91 Cr. | 805.03 Cr. | 736.33 Cr. | 658.32 Cr. |
| Cost of Revenue | 0 | 241.93 Cr. | 175.26 Cr. | 157.61 Cr. |
| Total Other Income Expense Net | 26.09 Cr. | 6.88 Cr. | 9.49 Cr. | 8.47 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | 0 | 355.13 Cr. | 296.50 Cr. | 291.14 Cr. |
| Net Income Applicable to Common Shares | 0 | 355.13 Cr. | 296.49 Cr. | 290.79 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 0 | 684.07 Cr. | 698.46 Cr. | 613.60 Cr. |
| Capital Surplus | 0 | 0 | 0 | 1.34 Cr. |
| Total Liabilities | 0 | 258.35 Cr. | 255.97 Cr. | 384.83 Cr. |
| Stock Holder Equity | 0 | 1576.42 Cr. | 1296.33 Cr. | 1150.51 Cr. |
| Minority Interest | 0 | 20 k | 0 | 18.31 Cr. |
| Other Liabilities | 65.64 Cr. | 34.23 Cr. | 30.61 Cr. | 20.02 Cr. |
| Total Assets | 0 | 1834.78 Cr. | 1552.30 Cr. | 1553.66 Cr. |
| Common Stock | 0 | 13.57 Cr. | 13.57 Cr. | 13.75 Cr. |
| Retained Earnings | 0 | 1550.31 Cr. | 1271.34 Cr. | 1134.22 Cr. |
| Other Liabilities | 0 | 86.97 Cr. | 85.13 Cr. | 79 Cr. |
| Good Will | 0 | 93.47 Cr. | 93.47 Cr. | 93.58 Cr. |
| Treasury Stock | 0 | 12.53 Cr. | 11.41 Cr. | 1.19 Cr. |
| Other Assets | 274.54 Cr. | 226.39 Cr. | 190.26 Cr. | 167.70 Cr. |
| Cash | 0 | 36.91 Cr. | 67.30 Cr. | 7.50 Cr. |
| Current Liabilities | 0 | 166.93 Cr. | 164.69 Cr. | 305.53 Cr. |
| Long Term Asset Charges | 0 | 200.63 Cr. | 170.91 Cr. | 144.79 Cr. |
| Short Long Term Debt | 0 | 0 | 0 | 176.13 Cr. |
| Other Stockholder Equity | 0 | 12.53 Cr. | 11.41 Cr. | 1.19 Cr. |
| Property Plant Equipment | 0 | 77.87 Cr. | 87.27 Cr. | 56.07 Cr. |
| Total Cur. Assets | 0 | 467.04 Cr. | 479.61 Cr. | 581.77 Cr. |
| Long Term Investments | 425.34 Cr. | 285.91 Cr. | 3.20 Cr. | 40.91 Cr. |
| Net Tangible Assets | 0 | 798.87 Cr. | 504.39 Cr. | 443.32 Cr. |
| Short Term Investments | 167.03 Cr. | 92.42 Cr. | 20 k | 20 k |
| Net Receivables | 0 | 172.53 Cr. | 206.90 Cr. | 136.80 Cr. |
| Long Term Debt | 0 | 0 | 0 | 29.30 Lakhs |
| Inventory | 0 | 94.46 Cr. | 69.47 Cr. | 82.65 Cr. |
| Accounts Payable | 0 | 102.61 Cr. | 100.05 Cr. | 84.12 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account